Paragon Advisors LLC Has $1.82 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Paragon Advisors LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,405 shares of the company’s stock after acquiring an additional 426 shares during the period. Paragon Advisors LLC’s holdings in IDEXX Laboratories were worth $1,821,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Czech National Bank raised its stake in shares of IDEXX Laboratories by 5.9% in the fourth quarter. Czech National Bank now owns 17,755 shares of the company’s stock worth $7,341,000 after purchasing an additional 989 shares during the last quarter. ST Germain D J Co. Inc. boosted its position in shares of IDEXX Laboratories by 517.2% during the fourth quarter. ST Germain D J Co. Inc. now owns 179 shares of the company’s stock valued at $74,000 after buying an additional 150 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in IDEXX Laboratories by 0.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 29,751 shares of the company’s stock worth $12,300,000 after buying an additional 117 shares in the last quarter. First Hawaiian Bank raised its position in IDEXX Laboratories by 32.5% in the 4th quarter. First Hawaiian Bank now owns 665 shares of the company’s stock valued at $275,000 after buying an additional 163 shares during the last quarter. Finally, Westwind Capital lifted its stake in IDEXX Laboratories by 2.8% during the 4th quarter. Westwind Capital now owns 44,662 shares of the company’s stock valued at $18,465,000 after acquiring an additional 1,211 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Barclays reduced their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. JPMorgan Chase & Co. reduced their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Piper Sandler reiterated a “neutral” rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Stifel Nicolaus cut their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $539.63.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 3.3 %

Shares of IDXX stock opened at $418.05 on Monday. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The firm has a market cap of $34.23 billion, a P/E ratio of 40.31, a PEG ratio of 3.94 and a beta of 1.36. The company has a 50 day moving average of $423.76 and a 200-day moving average of $459.98. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same period last year, the business posted $2.53 earnings per share. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.